Standout Papers

Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and U... 2015 2026 2018 2022 634
  1. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials (2015)
    C.E.M. Griffiths, Kristian Reich et al. The Lancet

Immediate Impact

13 by Nobel laureates 26 from Science/Nature 82 standout
Sub-graph 1 of 20

Citing Papers

Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial
2022 Standout
Psoriasis
2021 Standout
25 intermediate papers

Works of Michael Heffernan being referenced

Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials
2015 Standout
Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: Double-blind, randomized controlled trial and open-label extension study
2006
and 6 more

Author Peers

Author Last Decade Papers Cites
Michael Heffernan 562 1122 495 1601 64 3.1k
Thomas Barnetche 210 597 402 1715 123 4.4k
Amit K. Dey 654 238 173 1100 97 2.7k
Wietske Kievit 91 461 576 1115 169 4.0k
Bénédicte Lebrun‐Vignes 595 293 512 467 118 3.6k
Pierre Clerson 1197 434 1454 412 104 4.1k
Anja Strangfeld 184 212 381 939 134 3.7k
P. A. Bacon 137 316 411 953 63 3.6k
Marian T. McEvoy 55 1169 473 1249 75 3.1k
James B. Whitmore 403 104 172 1503 63 3.9k
S. E. Gabriel 276 179 375 435 38 2.8k

All Works

Loading papers...

Rankless by CCL
2026